Home > News > Starpharma’s VivaGel™ Advance to Third Stage
August 2nd, 2004
Starpharma’s VivaGel™ Advance to Third Stage
Abstract:
Starpharma Holdings Limited announced today that VivaGel™, its investigational new drug for the prevention of HIV, is advancing to the next stage of dosing in the current Phase 1 study. VivaGel™ is the first drug product in the world based upon nanoscale structures called dendrimers, to enter human trials.
Source:
Starpharma
Bookmark:
| Related News Press |
Nanomedicine
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||